Clinical and laboratory data of the eight MDR-TB patients with positive Xpert MTB/RIF sputum and culture.

<p>Legend: *According to WHO criteria [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0127536#pone.0127536.ref014" target="_blank">14</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0127536#pone.0127536.ref015" target="_blank">15</a>]; R, resistant; S, susceptible; INH, isoniazid; RIF, rifampin; ETB, etambutol; STR, streptomycin; PZA, pyrazinamide; AMK, amikacin; CAP, capreomycin; OFX, ofloxacin; RFB, rifabutin; ETH, ethionamide; PAS, paraaminosalicylic acid; MTBC, <i>M</i>. <i>tuberculosis</i> complex; TB, tuberculosis; DST, drug susceptibility testing; HIV, human immunodeficiency virus.</p><p>Clinical and laboratory data of the eight MDR-TB patients with positive Xpert MTB/RIF sputum and culture.</p

Dendogram based on the 24-<i>loci</i> MIRU-VNTR and spoligotyping profiles of the eight MDR <i>M</i>. <i>tuberculosis</i> isolates, with positive results with the Xpert MTB/RIF assay in Guinea-Bissau.

<p>The eight strains can be divided in two clades, Beijing and LAM9. Within the Beijing clade, two genetic clusters were detected; one comprised by strains #1 and #90 and the second one by strains #19 and #68. Distance scale is indicated at the bottom (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0127536#sec005" target="_blank">Methods</a> for further details). SIT, shared international type (from SITVIT WEB database).</p